Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trial

article

Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1080/17482960600888156
P698PubMed publication ID17364435

P50authorPaul H. GordonQ37837296
Hiroshi MitsumotoQ90084178
P2093author name stringPetra Kaufmann
Bruce Levin
Richard Buchsbaum
John L P Thompson
Alexandra I Barsdorf
Vanessa Battista
Rachel Arbing
Gilbero Levy
Jacquelina Montes
QALS study group
P2860cites workIntraclass correlations: uses in assessing rater reliabilityQ28296226
ALS issues in clinical trials. Missing dataQ30974065
ALSFRS-R.Q34362989
A clinical trial of creatine in ALS.Q40469445
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosisQ43569621
A randomized sequential trial of creatine in amyotrophic lateral sclerosisQ44383439
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosisQ44562245
A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS.Q46433161
Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study GroupQ46827288
The ALSFRSr predicts survival time in an ALS clinic populationQ47867763
Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trialsQ48570656
Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R.Q52980048
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).Q53535985
P433issue1
P921main subjectmulticenter clinical trialQ6934595
P304page(s)42-46
P577publication date2007-02-01
P1433published inAmyotrophic Lateral Sclerosis and Other Motor Neuron DisordersQ15759048
P1476titleExcellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial
P478volume8

Reverse relations

cites work (P2860)
Q57165581A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene
Q51636543A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements.
Q36177001A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement
Q37227808A plug-and-play brain-computer interface to operate commercial assistive technology
Q48266568A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN.
Q37317971Accurate ALSFRS-R scores can be generated from retrospective review of clinic notes
Q88409196Acute Effects of Riluzole and Retigabine on Axonal Excitability in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
Q40797810Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis
Q35042461Amyotrophic lateral sclerosis patients' self-reported satisfaction with assistive technology
Q33885448Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model
Q42668576Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study
Q57290390Chronic Traumatic Encephalopathy Within an Amyotrophic Lateral Sclerosis Brain Bank Cohort
Q64228443Clinical Measures of Bulbar Dysfunction in ALS
Q35501852Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis
Q37513013Clinical outcome measures in spinal muscular atrophy
Q92289432Dominant Heterogeneity of Upper and Lower Motor Neuron Degeneration to Motor Manifestation of Involved Region in Amyotrophic Lateral Sclerosis
Q44317416Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses
Q46710455Elective termination of respiratory therapy in amyotrophic lateral sclerosis
Q37867784Emerging targets and treatments in amyotrophic lateral sclerosis
Q48211357Eye tracking communication devices in amyotrophic lateral sclerosis: impact on disability and quality of life
Q51066498Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients.
Q90317315First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound
Q44215931Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study
Q52731289Global motor unit number index sum score for assessing the loss of lower motor neurons in amyotrophic lateral sclerosis.
Q43739867Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality
Q41553914Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy
Q35367839Identification of personal factors in motor neurone disease: a pilot study
Q89962935Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer
Q30488429Item response theory analysis of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised in the Pooled Resource Open-Access ALS Clinical Trials Database
Q58096837Minimally Detectable Change and Minimal Clinically Important Difference of a Decline in Sentence Intelligibility and Speaking Rate for Individuals With Amyotrophic Lateral Sclerosis
Q51643746Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease
Q48052700Multidisciplinary ALS clinics in the USA: A comparison of those who attend and those who do not.
Q43603184Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients
Q39215223Non-self-sufficiency as a primary outcome measure in ALS trials
Q92378843Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS
Q35847073Online assessment of ALS functional rating scale compares well to in-clinic evaluation: a prospective trial
Q41837997Outcome measures in amyotrophic lateral sclerosis clinical trials
Q34429131Patterns of spontaneous brain activity in amyotrophic lateral sclerosis: a resting-state FMRI study
Q30494108Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.
Q34026859Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
Q30359919Speech Movement Measures as Markers of Bulbar Disease in Amyotrophic Lateral Sclerosis.
Q55982486Spinal muscular atrophy
Q60634009The Clinical and Radiological Spectrum of Hippocampal Pathology in Amyotrophic Lateral Sclerosis
Q50204979The diagnostic utility of patient-report and speech-language pathologists' ratings for detecting the early onset of bulbar symptoms due to ALS.
Q56773744The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis
Q36441993The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials
Q42619674Use of the international classification of functioning, disability and health to describe patient-reported disability: a comparison of motor neurone disease, Guillain-Barré syndrome and multiple sclerosis in an Australian cohort
Q45284849Validation of the German version of the extended ALS functional rating scale as a patient-reported outcome measure
Q35776967What would brain-computer interface users want? Opinions and priorities of potential users with amyotrophic lateral sclerosis

Search more.